Literature DB >> 21114636

HSP-27 protein expression in uveal melanoma: correlation with predicted survival.

Fidan Jmor1, Helen Kalirai, Azzam Taktak, Bertil Damato, Sarah E Coupland.   

Abstract

PURPOSE: Almost 40% of uveal melanomas (UM) are fatal, because of metastatic disease that usually involves the liver. Partial or complete deletion of chromosome 3 (i.e., monosomy 3) is a strong predictor of metastatic mortality; however, genetic analysis is not always possible. The aim of this study was to determine whether heat shock protein 27 (HSP-27) protein expression could reliably predict prognosis.
METHODS: Immunohistochemical analysis of HSP-27 protein expression was performed on formalin-fixed, paraffin-embedded sections from 99 UM of known chromosome 3 status, as determined by multiplex ligation-dependent probe amplification. Slides were evaluated blind by three independent observers. The percentage of tumour cells staining for HSP-27 was categorized as: 0 (<1%); 1 (1-24%); 2 (25-49%); 3 (50-74%) or 4 (>74%). The staining intensity was categorized as: 0 (no staining); 1 (weak); 2 (moderate) and 3 (strong). These two categories were multiplied together to obtain the HSP-27 expression score. All data were processed in spss for statistical analyses.
RESULTS: Heat shock protein 27 score was lower in monosomy 3 melanomas than in disomy 3 tumours (p<0.001; Mann-Whitney U-test). An 'accelerated failure time model' was used to generate predicted survival for all patients included in the study. Kaplan-Meier analysis indicated a significantly decreased predicted 8-year survival rate for patients with an HSP-27 Score≤6 (p=0.03; Log rank test). Predicting monosomy 3 was enhanced by considering the HSP-27 score together with basal tumour diameter, melanoma cytomorphology and mitotic rate.
CONCLUSIONS: Low HSP-27 expression correlates with monosomy 3 in UM and with increased predicted mortality. When assessed together with other clinical and pathological variables, the HSP-27 score enhances estimation of survival probability.
© 2010 The Authors. Acta Ophthalmologica © 2010 Acta Ophthalmologica Scandinavica Foundation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21114636     DOI: 10.1111/j.1755-3768.2010.02038.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  12 in total

1.  Conjunctival squamous cell neoplasia: the Liverpool Ocular Oncology Centre experience.

Authors:  N Kenawy; A Garrick; H Heimann; S E Coupland; B E Damato
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-16       Impact factor: 3.117

2.  Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture.

Authors:  B Damato
Journal:  Eye (Lond)       Date:  2012-06-29       Impact factor: 3.775

Review 3.  The protective role of HSP27 in ocular diseases.

Authors:  K Sooraj; Swati Shukla; Ranjeet Kaur; Jeewan Singh Titiyal; Jasbir Kaur
Journal:  Mol Biol Rep       Date:  2022-02-25       Impact factor: 2.742

4.  Ocular melanoma.

Authors:  Bertil E Damato; Sarah E Coupland
Journal:  Saudi J Ophthalmol       Date:  2012-04

Review 5.  Proteomics in uveal melanoma.

Authors:  Michael J Heiferman; Vinit B Mahajan; Prithvi Mruthyunjaya
Journal:  Curr Opin Ophthalmol       Date:  2022-01-31       Impact factor: 4.299

6.  Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.

Authors:  Kathleen J Till; Andrew R Pettitt; Joseph R Slupsky
Journal:  J Immunol       Date:  2015-01-28       Impact factor: 5.422

7.  Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins.

Authors:  Stephen Middle; Sarah E Coupland; Azzam Taktak; Victoria Kidgell; Joseph R Slupsky; Andrew R Pettitt; Kathleen J Till
Journal:  Exp Hematol Oncol       Date:  2015-04-01

Review 8.  Proteomics of uveal melanoma: a minireview.

Authors:  Søren K O Abildgaard; Henrik Vorum
Journal:  J Oncol       Date:  2013-09-03       Impact factor: 4.375

9.  iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors.

Authors:  John W Crabb; Bo Hu; John S Crabb; Pierre Triozzi; Yogen Saunthararajah; Raymond Tubbs; Arun D Singh
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

10.  Clinico-Pathological Association of Delineated miRNAs in Uveal Melanoma with Monosomy 3/Disomy 3 Chromosomal Aberrations.

Authors:  Nalini Venkatesan; Jagat Kanwar; Perinkulam Ravi Deepa; Vikas Khetan; Tamsyn M Crowley; Rajeswari Raguraman; Ganesan Sugneswari; Pukhraj Rishi; Viswanathan Natarajan; Jyotirmay Biswas; Subramanian Krishnakumar
Journal:  PLoS One       Date:  2016-01-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.